Welcome to our dedicated page for Bioventus news (Ticker: BVS), a resource for investors and traders seeking the latest updates and insights on Bioventus stock.
Bioventus Inc. (Nasdaq: BVS) is a medical technology company that describes itself as a global leader in innovations for active healing. The Bioventus news stream features company announcements, financial updates and product milestones that reflect its focus on Pain Treatments, Surgical Solutions and Restorative Therapies.
Investors following BVS news will find regular earnings releases where Bioventus reports net sales, segment performance across Pain Treatments, Surgical Solutions and Restorative Therapies, and metrics such as net income, Adjusted EBITDA and non-GAAP earnings. These updates often include commentary on organic revenue trends, portfolio changes like the divestiture of the Advanced Rehabilitation Business, and the impact of factors such as foreign currency and tariffs.
The company also issues product and regulatory news, including announcements of U.S. Food and Drug Administration (FDA) 510(k) clearances. Recent examples include clearances for TalisMann and StimTrial, two Peripheral Nerve Stimulation products for chronic pain management that Bioventus highlights as expanding its non-opioid, minimally invasive therapy portfolio.
Bioventus news items cover capital structure and financing developments, such as the entry into a new senior secured credit agreement that refinanced prior debt, increased revolving capacity and reduced interest margins. In addition, the company regularly announces participation in major healthcare and investor conferences hosted by firms such as J.P. Morgan, Piper Sandler, Morgan Stanley and Canaccord Genuity.
For readers tracking BVS, the news page provides a centralized view of Bioventus’ financial performance, product pipeline progress, regulatory milestones and corporate events, helping contextualize how its Pain Treatments, Surgical Solutions and Restorative Therapies businesses evolve over time.
Bioventus (Nasdaq: BVS) and Misonix (Nasdaq: MSON) announced an election deadline of October 25, 2021, for Misonix stockholders to choose their preferred merger consideration in the proposed acquisition. Each Misonix share will convert to either 1.6839 shares of Bioventus Class A stock or $28.00 in cash, with the option for hybrid election. Record holders must return their Letter of Election and Transmittal to the Exchange Agent by the deadline. A special meeting for stockholders to vote on the merger is set for October 26, 2021. This merger is expected to enhance Bioventus’ product offerings.
Bioventus (Nasdaq: BVS) announced that the American Academy of Orthopaedic Surgeons (AAOS) has released updated clinical practice guidelines (CPG) endorsing the use of high molecular weight cross-linked hyaluronic acid treatments, including DUROLANE, for knee osteoarthritis (OA). The guidelines highlight the effectiveness of these treatments for patients with low to moderate OA who have not responded to other therapies. DUROLANE is noted for its significant pain relief benefits and safety profile. The recommendations are aligned with Bioventus’s clinical practices.
Bioventus (Nasdaq: BVS) announced a $50 million escrow payment as part of its acquisition process for CartiHeal Ltd., indicating strong intent to advance this deal. This decision follows a thorough review of clinical data for the Agili-C implant, which has received FDA's Breakthrough Device Designation. Agili-C aims to treat cartilage defects in the knee, presenting a market opportunity for up to 650,000 patients annually. Bioventus will collaborate with CartiHeal ahead of potential FDA approval to prepare for commercialization efforts.
Bioventus Inc. (Nasdaq: BVS) has announced a strategic investment in Trice Medical, securing exclusive sales and distribution rights for Trice’s products outside the US. This investment includes a co-development agreement to integrate Trice’s technologies with Bioventus’ peripheral nerve stimulation offerings, enhancing product adoption. Trice, known for its innovative surgical devices, aims to improve patient recovery and reduce costs. This alliance aligns with Bioventus' strategy to expand its portfolio in the sports medicine and orthopedic sectors.
Bioventus (Nasdaq: BVS) has appointed Dave Crawford as Vice President, Investor Relations and Treasurer, bringing over 20 years of finance experience to the role. Previously with Avanos Medical, Crawford has a strong background in finance and treasury from Kimberly-Clark and Eli Lilly. His MBA is from Duke University, and he holds a Bachelor’s in Accounting from Notre Dame. The company continues to focus on delivering clinically proven, cost-effective products for healing.
SV Health Investors, a global healthcare investment firm, announced significant realizations from its growth equity portfolio. HillRom acquired Bardy Diagnostics on August 6, enhancing its ambulatory cardiac monitoring services. Healthify agreed to be acquired by WellSky, focusing on integrating social services into healthcare. Additionally, Bioventus announced a cash and stock deal to acquire Misonix, a company supported by SV since 2017. SV's initiatives align with its strategy of driving growth and enhancing patient access while managing $2.6B in assets.
Bioventus reported Q2 financial results for 2021, achieving net sales of $109.8 million, an increase of 89.3% year-over-year. This includes $97.9 million from legacy operations and $11.9 million from Bioness Inc. acquisition. Despite a net loss of $10.8 million, this reflects an increase of 80.3% year-over-year. Adjusted EBITDA rose to $19.9 million, up 186.5% year-over-year. The company updated its full-year guidance, projecting net sales growth of 26% to 29% and increased total addressable market to $15 billion.
Bioventus Announces Acquisition of Misonix
Bioventus will acquire Misonix in a cash-and-stock deal valued at approximately $518 million, enhancing its product portfolio and revenue. The transaction involves Misonix stockholders choosing between 1.6839 shares of Bioventus stock or $28.00 in cash. Once completed, the merger aims to accelerate growth opportunities, adding nearly $80 million in revenue for 2021 and generating $20 million in annual cost synergies by year two. The deal awaits regulatory and stockholder approvals, expected to finalize in Q4 2021.
Bioventus Inc. (Nasdaq: BVS) reported preliminary second quarter net sales of $108 million to $110 million, reflecting an impressive 86.2% to 89.7% year-over-year growth. This includes $96.5 million to $98.0 million from legacy operations and $11.5 million to $12.0 million from the recent acquisition of Bioness Inc. Updated full-year guidance anticipates net sales of $405 million to $415 million, marking a 26% to 29% increase. Bioventus also announced its intention to acquire Misonix, expanding its product portfolio in regenerative medicine.
DURHAM, N.C., July 27, 2021 - Bioventus (Nasdaq: BVS) will participate in two virtual conferences: the Canaccord Genuity 41st Annual Growth Conference on August 12 at 3:30 p.m. ET and the Morgan Stanley Virtual Global Healthcare Conference on September 10 at 9:30 a.m. ET. Presentation materials will be available in the investor relations section of the Bioventus website before each event, alongside live audio webcasts and replays accessible for 30 days. Bioventus focuses on clinically proven products for active healing.